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Objectives: Upon completion of this article, the reader will be
able to identify the role of laparoscopic assistance during
microwave or radiofrequency ablation of liver tumors.
Accreditation: This activity has been planned and imple-
mented in accordancewith the Essential Areas and Policies of
the Accreditation Council for Continuing Medical Education
(ACCME) through the joint providership of Tufts University
School of Medicine (TUSM) and Thieme Medical Publishers,
New York. TUSM is accredited by the ACCME to provide
continuing medical education for physicians.
Credit: Tufts University School of Medicine designates this
journal-based CME activity for a maximum of 1 AMA PRA
Category 1 Credit™. Physicians should claim only the credit
commensurate with the extent of their participation in the
activity.
Georg Kelling performed the first laparoscopic procedure
in his laboratory in 1901.1 In the late 20th century due to
advancements in lens design and optical projection, laparos-
copy achieved global acceptance. The field has progressed
from a purely diagnostic instrument to one capable of ad-
vanced intervention. Laparoscopy is extensively used in
patients with benign disease, as well as those with advanced
malignancy. Over the past 15 years, there has been a growing
interest in utilizing laparoscopy to facilitate the delivery of
thermoablative therapies for primary (►Fig. 1) and second-
ary tumors of the liver. This article will provide a summary
and insight into the current state of laparoscopic thermal
ablation in hepatic malignancies.
The local ablative modalities most frequently used to treat
liver tumors are radiofrequency (RF) and microwave (MW).
For this reason, other local ablative therapies, such as cryo-
therapy, ethanol injection, and laser-induced thermotherapy
will not be discussed. RF is delivered via an insulated probe
with an exposed tip. The RF generator provides an alternating
current causing the oscillation of ions, resulting in a tissue
temperature of up to 100°C. The heat dissipates throughout
the tissue surrounding the probe, and the increase in local
temperature results in protein denaturation ultimately lead-
ing to cellular destruction and tissue necrosis.2 Although it
provides a similar result MW energy ablation functions
through a different mechanism, the MW generator produces
electromagnetic radiation (EMR) within the MW spectrum,
which is absorbed by water molecules. This EMR causes
molecular rotation, resulting in the creation of thermal
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either technique, ablation zones are predetermined by limit-
ing the amount of energy supplied, or by the time the tissue is
exposed to the energy source.
RF ablation (RFA) and MW ablation (MWA) have been
described as a treatment for primary and secondary malig-
nancies in the liver. The most common applications are in
patients with hepatocellular carcinoma (HCC), and in those
with hepatic metastases from colorectal carcinoma (colorec-
tal cancer liver metastases [CRLM]).4–20 The indications for
laparoscopic RFA orMWA can be divided into patient-specific
and tumor-specific categories. In discussing indications for
laparoscopic thermal ablation, it should be noted that surgical
resectionwith tumor-freemargins remains the accepted gold
standard of therapy for both HCC and CRLM.21–26
The most frequent presentation of HCC is in the setting of
cirrhosis. Additional risk factors for the development of HCC
include concomitant infection with hepatitis C and/or hepa-
titis B.27 Typically, these patients are not eligible for partial
hepatectomy due to insufficient hepatic reserve and are
subsequently evaluated for alternative options, including
but not limited to thermal ablation or liver transplantation.28
With regard to CRLM, patients often undergo thermal abla-
tion due to the presumption that they would be unable to
tolerate the magnitude of partial hepatectomy due to co-
morbidities. Tumor-specific characteristics can also limit
patients’ options in treating either HCC or CRLM. Patients
with technically unresectable disease, multicentric disease,
and bilobar disease are also candidates for laparoscopic
thermal ablation.
Safety/Morbidity/Mortality
The safety of laparoscopic RFA and MWA is well described in
the literature. Complication rates vary from 2 to
62%.4,5,10–12,14,16,19,20 Morbidity from RFA ranges from 2 to
45%,4,11,12,14 whereas the rates for MWA range from 16 to
62%.4,5,20 The majority of complications are minor; however,
deaths have been reported after both procedures.4,9
Efficacy
Hepatocellular Carcinoma
RFA andMWAtreatment inHCC are localmodalities typically
used in patients who are not candidates for surgical resec-
tion. Since anatomic resections are not possible, the necessity
for complete ablation is vital. Incomplete laparoscopic abla-
tion rates from 5.6 to 13% have been published5,6; local
recurrence rates range from 2.9 to 22% with a varying range
of follow-up.5,6,9 In addition to local recurrence, intrahepatic
recurrence and the development of de novo malignancies
poses a significant clinical challenge. In a retrospective
review of 92 patients undergoing laparoscopic RFA for
HCC, Karabulut et al noted a new liver recurrence in 57% of
patients with a median follow-up of 19 months. This was in
comparison to a 46% recurrence rate in 92 patients undergo-
ing liver resection for HCC (p ¼ 0.167).9 Similarly, Santam-
brogio et al published a regional recurrence rate of 30% after
laparoscopic RFA for HCC in 102 patients during an unspeci-
fied time of follow-up.6
The effects of laparoscopic thermal ablation on survival
have also been described. Swan et al published a 1-year
survival rate of 72.3% in 54 patients with HCC and cirrhosis
following laparoscopic MWA.5 Berber et al found a similar
1-year overall survival rate of 78% after laparoscopic RFA in 66
cirrhotic patients with HCC.8 Ballem et al describe a 3-year
survival rate of 21% in 104 patients undergoing 122 ablations
for HCC using RF.7 In the 66 patients presented by Berber et al,
a 3-year survival rate of 38% was acheived.8 When reported,
5-year survival rates ranged from 8.3 to 21%.7,9
Several authors have shown an increased survival advan-
tage based on child class.5,7,8 Swan et al show a 1- and 2-year
overall survival rate of 71 and 63% for Child A cirrhotics,
whereas this falls to 65 and 52% in Child B and C, respectively.5
Ballem et al and Berber et al found similar median survival in
their respective subgroup analyses based on the degree of
hepatic dysfunction. In both studies, median survival for
Child A was 28 to 29 months, but only 5 to 5.9 months for
Child C patients7,8 (Berber et al8 reached statistical signifi-
cance with a p value < 0.001).
Colorectal Liver Metastases
Similar to HCC, < 20% of patients presenting with liver
metastases from colorectal carcinoma are eligible for curative
resection.29 In addition, local recurrence rates have been
problematic for these patients. The local recurrence rates
range from 9.2 to 34%.13,15,16 Over a 10-year experience with
130 patients, Kennedy et al showed a local recurrence rate of
9.2%. However, a subgroup analysis restricted to patientswith
tumors > 3 cm in size demonstrates local recurrence rates
blossoming to 19.6%.16 Aksoy et al described a de novo
recurrence rate of 43% in 252 patients with CRLM undergoing
laparoscopic RFA. Multivariate analysis of this group showed
patients with a tumor size > 5 cm were twice as likely to
recur locally when compared with patients with tumor
size < 3 cm. They also showed patients with an ablation
margin of < 1 cm retained a similar risk when compared
with those with a margin > 2 cm.13 Berber et al also
Figure 1 A microwave ablation antenna (black arrow) is demon-
strated within the hepatic parenchyma during ablation. A four-way
ultrasound probe (white arrow) is located immediately adjacent to the
microwave antenna.
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demonstrated that local tumor control improved with larger
ablation margins.15
Five-year survival rates for hepatic resection in CRLM are
as high as 59%.30–33 Laparoscopic RFA has been unable to
match this efficacy in survival. Aksoy et al reported a 5-year
survival rate of 47% in 252 patients; however, the inclusion
criteriawere limited to thosewith tumors  3 cm.13Hammill
et al described a retrospective review of 101 patients under-
going laparoscopic RFA for CRLM. Upon review of preopera-
tive imaging, a blinded hepatobiliary surgeon determined 64
of those patients were technically resectable. The 5-year
survival for those who were technically resectable was 48.7
versus 18.4% for those deemed unresectable.12 Two different
studies demonstrate similar 5-year survival rates of approxi-
mately 30%.14,16
Other Secondary Malignancies
Laparoscopic RFA has been described in multiple secondary
hepatic malignancies other than metastatic colorectal cancer.
Outcomes from laparoscopic RFA treatment of liver metasta-
ses from breast cancer, neuroendocrine tumors, melanoma,
sarcoma, and others have been published.34–36 These are
primarily case reports and small clinical series. Given the
paucity of data, laparoscopic thermal ablation should not be
considered in the algorithm for standard treatment of these
tumors.
Laparoscopic Ultrasound
One of themajor advantages of laparoscopic thermal ablation
is the inherent surgical staging that precedes an intervention.
Some clinicians have advocated for diagnostic laparoscopy
before open partial hepatectomy for cancer to ensure a
patient’s candidacy for curative resection.29 The rationale
for this approach is to avoid the morbidity associated with
laparotomy for those patients who would not benefit from
the planned resection. This concept can be applied to laparo-
scopic thermal ablation as well. Santambrogio et al reported
on 153 HCC nodules identified preoperatively by transcuta-
neous ultrasound, triple-phase computed tomography (CT),
or magnetic resonance imaging (MRI). Only one patient had
an MRI. At the time of operation, laparoscopic ultrasound
located 26 new malignant lesions that were missed by
preoperative imaging. These tumors ranged in size from 4
to 23mm.6 In a series of 72 cirrhotic patients with a variety of
malignant hepatic tumors, Salama et al identified 19 new
malignant lesions with ultrasound at the time of laparoscopy.
Preoperative imaging included triple-phase CT and MRI. The
median diameter of these tumors was not specified.18
Conclusion
Current results with laparoscopic thermal ablation have not
demonstrated efficacy that would allow either laparoscopic
RFA or MWA to supplant surgical resection as primary
therapy for either HCC or CRLM. However, the role of laparo-
scopic RFA and MWA continues to evolve. The reported
complication rates associated with laparoscopic MWA are
surprisingly frequent considering it is a minimally invasive
approach. However, the vast majority of the literature on
laparoscopic MWA involves patients with HCC and cirrhosis.
It is well established that cirrhotic patients are high-risk
surgical candidates, and as such more likely to incur postop-
erative morbidity. The complication rates with MWA are
more likely related to the patients underlying liver disease
rather than the modality itself.
Laparoscopic RFA and MWA have also been criticized for
unacceptable local recurrence rates. Although the rates are
higher than surgical resection, the data are impacted by
selection bias. The majority of studies reporting on the topic
of ablation involve patients allocated to thermal ablation by
some means other than randomization. The heterogeneity of
the population treated with laparoscopic thermal ablation
makes it extremely difficult to draw any meaningful con-
clusions regarding the efficacy of laparoscopic RFA or MWA.
In addition to the questions arising from the selection criteria
of the patient population, the impact of heterogeneity of the
modalities used must also be studied. Padma et al described
the evolution of generators used in RFA, as well as those
available for MWA; advances in generators and probes over
the last 10þ years likely contribute to some of the differences
in outcomes. In addition, RFA and MWA are not equal
modalities. MWA provides higher intratumoral tempera-
tures, a more predictable ablation zone, and it is not suscep-
tible to the “heat sink” phenomenon that afflicts RFA.3
Hepatic thermal ablation can be delivered via an open,
laparoscopic, or percutaneous approach.17 The percutaneous
approach relies solely on radiographic staging and can be
limited by the anatomic location of the tumor(s) within the
liver. Some of these anatomic limitations can be overcome
with laparoscopic assistance that provides a different trajec-
tory for placement of the ablation probes. In addition, lapa-
roscopy may provide some benefit in detecting subtle
extrahepatic disease, which may alter the planned course
of treatment.
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